Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Urinary Urgency Incontinence

Tundra lists 3 Urinary Urgency Incontinence clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06511141

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-03-12

14 states

Overactive Bladder
Urinary Urgency Incontinence
Benign Prostatic Hyperplasia
+3
RECRUITING

NCT07144813

Post-Approval Study of the Neuspera Sacral Neuromodulation System

Prospective, multi-center, single-arm, post-approval study is designed to assess the long-term safety and efficacy data of the Neuspera Sacral Neuromodulation (SNM) System following commercial approval of the Neuspera SNM System. Participants in this study received intervention/implanted in Phase I or Phase II of the Neuspera SANS\_UUI (NSM-004) Study.

Gender: All

Ages: 22 Years - Any

Updated: 2026-02-04

17 states

Urinary Urgency Incontinence
ACTIVE NOT RECRUITING

NCT04232696

Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)

Prospective, multi-center, single-arm, seamless phase-pivotal study conducted in participants diagnosed with UUI who have failed or could not tolerate more conservative treatment. The trial will be conducted in two phases. Objective of Phase I: To assess the utilization of the system during the Sacral Nerve Stimulation (SNS) trial period and to help inform the length of hours of daily stimulation to be used in Phase II of the trial. Objective of Phase II: To assess the safety and efficacy of the Neuspera SNS System at 6-months for the primary efficacy endpoint and at 12 months for secondary safety and efficacy endpoints.

Gender: All

Ages: 22 Years - Any

Updated: 2025-11-03

20 states

Urinary Urgency Incontinence